Large-cell lymphoma in four cats after successful treatment of feline infectious peritonitis with oral GS-441524: a novel clinical observation

Abstract

Case series summary Fatal feline infectious peritonitis (FIP), caused by feline coronavirus (FCoV), can now be cured with GS-441524. Only a few unexpected clinical and laboratory observations have been reported with treatment, including lymphocytosis, eosinophilia and long-term persistence of abdominal lymphadenomegaly. Yet immune overstimulation associated with FIP might have negative long-term consequences. This report describes four cases of large-cell lymphoma (LCL) arising within 2 years of FIP diagnosis and successful treatment with legally sourced oral GS-441524 (15 mg/kg q24h), representing an incidence of 2.0% (n = 4/202) in a large treatment cohort. At LCL diagnosis, two cats were aged under 2 years, one was aged 8 years and one was aged 13 years. All cats showed weight loss, three had hyporexia and two had chronic vomiting; all tested negative for feline leukaemia virus and feline immunodeficiency virus. LCL was diagnosed by histology (n = 3) or cytology (n = 1) at 81, 365 (n = 2) and 595 days after FIP diagnosis/treatment start. The cats died a median of 15.5 days after LCL diagnosis. Neither a high FCoV viral load nor FCoV antigen, as determined by semi-quantitative RT-PCR and immunohistochemistry, respectively, was detected in any of the available samples. PCR for antigen receptor rearrangements revealed a monoclonal B-cell population in two cats, supporting a diagnosis of large B-cell lymphoma. Relevance and novel information The incidence of LCL reported here among cats in remission from FIP after legally sourced oral GS-441524 treatment is remarkably high compared with the general feline population. LCL should be considered a potential ‘long-FIP syndrome’ and/or a long-term complication after GS-441524 treatment. The pathogenesis of LCL in this context requires further clarification.